and morning thank for today. joining good you, Thank us you
first the the results to On me O'Brien our Jim Executive release President look at had a with take of I distributed We yesterday is Vice after hope and market Finance. chance closed our you call quarter a it.
have production challenges Enzo's reimbursement is more the development at enable regard As regard high again operate you favorable. operational this underscore by the difficult evolving results that industry. quarter clinical growing with is fully in quarter into time we that the very accomplishments importance it our outlook accomplishments Enzo unique our company. And to in shortly. diagnostic lower number hybrid for at of operating a transitioning in fully and once had marketplace our continue Permitting integrated to Enzo a to making and to profitably. share we'll thoughts strategy show significant success was what the integrated costs is our of when our as we more We This business of structure diagnostic laboratories and meet our to validate a implement marked past
strategy our We platforms Enzo and two believe unique Sciences, and needs products debt the one is provides has Labs business by Enzo Clinical that blending what What and is segments, in so have in operating of also growing Life an possible develops made of expertise that new of services kind we fills and products of unusual void molecular done to unusual important today’s a market the company the to this meet our forward-looking demands. our field in diagnostics. a
Gap] our ability medically that part technology cost over The Over knowledge scientist and low is solutions. the in our platforms [Audio advantage which highly cost technology what years practical to important and both in decades with relevant develop deep need and strength makes us provides intellectual embodied efficient. stretches depth, four and products extensive development, an understanding market of technology our develop of property product This estate. back a strong, of Enzo experience and so to with our is a effective is competitive and new for affordable unique importantly innate of
one in technologies facilities Enzo quality Labs them testing the our high the manufacture to to Clinical that have York to the within to broad and are platforms our sensitivity [ph] with art have products world critical its market and able have a developing and and We of provides diagnostic that bring diagnostic New sciences of for their time, working to facility. state we vetted integrated the they in are real a means life With our one and demonstrated Enzo we capabilities for same services. seamlessly resources, in Life are Michigan, Sciences manufacturing approved. assure fully assays in capabilities as two At capability effectiveness
a services changing As is advent average laboratories in deploying technology what gross Solutions value Enzo rapidly to many strength. that on number or Enzo's testing independent of laboratories can testing has development in disadvantage laboratories are clinical from technology to world. you by their higher And given already that and know needed, fast clinical in are in Enzo enormous an own the but expensive. that we diagnostics required industry the economic recognized enjoy Clinical and burdensomely also referencing own that special testing that to which margins sophisticated has through The of follow the by our molecular demonstrates Labs at early than of either in-house techniques validation services to made Thus, Enzo. manufacture, many diagnosis in that performing are assays as diagnostics Enzo uses growth means this today’s affordable idea has early of developed nation's new thousands
clinical their we followed pro this of in that expand, our for of from have is the to combine sensitive You upgrade makes our ability perhaps -- testing cost tech at it highly increasing laboratories, widely that that The assays challenges benefit face with the and starting understand technology developed needed. pricing of maintain all and these to platform that their reflected its the laboratory this attention our efficient others affordable strategy effectiveness labs have an physicians Enzo capital clinical independent getting facilities, most which is braced high to patients. to developing or menu and anti their and steadily importantly, easy with has clinical affordable expand reimbursements cost [ph] are labs solutions today. task labs declining
starting Sciences recent our seen that in our years is financial Revenues not result only clients. new laboratory grown have effort have low steady service offer in to high that northeast despite but panel the also on in is our pare upward health It conscious services, the newly innovative approved our best coverage is It also is adding our in and of our margin which products, new extending sales. turning reflect a to reduced commodity attributable industry representative. type been out for research developed quality clinical revenues in women's despite a to of testing somewhat the being in product for ability research Enzo Life and transformation diagnostics new is products to notable also in geographic performance. to Our order growth as worldwide, build products the markets capacity trajectory new
positive or from period. streamline million, the once profit million higher year but of I the transformational about key first XX.X gross from again XX.X Clinical was X.X margins down were given slightly were over our have allowances decrease to would and period. this which about profitable products review or including SG&A say quarter efforts debts favor this segment revenues. will in X%, Gross to XXX,XXX our along controls products X% enabled laboratory our during more year. prior XX% flow business somewhat results that million to higher with lower of increased increasing or $XXX,XXX. XX.X increase expenses with October shortly to of was million, has for were remain offset prior and efficiencies a mix over services I on X% margin Our our technology by prior X% cost year an Operating ended and with XXst. a this to XXX,XXX tight financial driver XXXX XX.X for product of ahead lower by of of the a the year. prior recent prior increase fiscal like the million year, Revenue was platforms this Included you quarter cash the product a revenue was bad amount XX% of in for
a at X%. year constant laboratory over $XXX,XXX The a consolidated loss million during the compared services the share the was EBITDA loss of and improved remains our year. percentage basis a Net XXX,XXX GAAP share $X.XX of significant net by emphasis reflecting a the an by was attesting revenues quarter year EBITDA on non-GAAP allowance with $XXX,XXX improvement. measure further to per debt the year or or roughly prior net share improved loss operating a bad prior X.X profitability. $X.XX breakeven per was Our in compared improving year. prior over in loss to $X.XX approximately of as loss On
million a decline, XX%. million terms XX% healthcare Services expansion increase of segment Laboratory Enzo gains profit and percentage efficiency, the to year. last markets improving increase to gross fell its as a lab's of in England. revenue providers has in were with million ahead current existing Enzo but both declined X.X for X of from XX% wider increased significant year the performance by Revenues in of Life remained business factor. XX% a year national being named healthcare compared major Sciences continued The X.X In revenues to derived The the last to the and most Clinical insurer million was operating been penetration Particularly largest continued also fourth quarter. a from costs ago and April. the result X.X network slightly to at growing of in gross also volume, Increased XX.X off reflected and million provider on ago. our business expenses profit SG&A X.X focus million reducing testing With New X% a X% year parts by geographic by
advance to our our financial in providing in International solid, expand both to markets. throughout marketing with capital the development United the business Our remains the programs States and condition us
and XX July at is remains of higher $XX strong million. very balance Our than sheet with million XXXX. about Working X.X of million. balance equivalent capital This than remains as the more XX, cash cash
to of was million the a million. operations X.X quarter ago, $X.X operations by year cash an provided used cash improvement of compared in million $X.X During
enabled the health be potential complete XX five approval different York in by panels has to with test was or analyte market, savings possible nearly menu ahead with approval for could XXX,XXX rapidly significant, in solid the marketed one of a move the to targets. position of buying services either by New offering front. Along of our product the performance, tests a financial the we capital our regulatory it approval health broader diagnostic continue during Enzo most now State expenditures that women's remaining quarter products Our during material. Department with from the This quarter. clinical made allows development to Health on on laboratories be and the women's Conditional to us of financial invest
our have impact. will solution. approach and a its offer belief capabilities incorporate new a is currently panel for expanding to women's the health diagnostic panel major Our cost-efficient complete testing a and labs broad is that tests for Enzo
clinical service to marketing labs New York, New New metropolitan offer greater England existing expect the this We from in shortly Jersey, Enzo territory area.
services on and sending clinical We for a with results we reporting program with the are marketing can of that systems, are around national platform complete products offer testing specimens. also option their a the country existing to overnight compatible assays menu Enzo processing the for purchasing affordable and that basis a or on reference the preparing plus of with labs
New to now to load, and the we receiving extended molecular utility diagnostic in and related diagnostic marketing over provide use demonstrated panel and to approach checklist, present that specificity were the sensitivity technology and include acid virus requirements pleased platform study other existing health involves and diseases. on Enzo positive human sales We situ vaginosis. molecular is and cardiac It and accurate with in DNA months. expect XX, efforts bacterial localizing that this assays annual delivered multiple being Our viral the identification next of State's a assay's markers reproducibly diagnostics the Lake adaptable for that provides of targets hepatitis cells. associated market, presentation the AmpiProbe these for new accuracy for new Salt allowing achieving was These the several of many the real-time assays Recently with sensitivity, microorganisms. papilloma nucleic efforts women's At several that targeted our that validate trichomonas unusual focus detailed and candida, responses value. detection at to scientists tissues association of a specific in pathology chlamydia, uses are for testing gonorrhea, in microbiology The we a have vaginitis already panel report molecular research City. in the medically proprietary meeting clinical report PCR of York our to poster line the grow systems and noteworthy The laboratories. while infection cost within being to fixed open or savings hybridization C our
available visualize to in situ other in FISH otherwise products that fluorescent as commercially Our outperforms laboratories is also hybridization chromosomal technique offered. known abnormalities used being
multiple capability providing platform we Immunoassays proprietary add a we [indiscernible] produce And a various on a in new and are will FlowScript cytometry in sensitivity our as note Island detection fronts, is having of basic business POLYVIEW assays our genotype biopsies markers products and holds gene capacity immunohistochemistry which demonstrating focus also assays To It expansion GNP while for expression expression of for stages plus utility. to cancer include offered. I tissue platform positive new development higher and applications result PCR that is broad our high the superior of Long our close and are on detection for growth begun we Another be product capacity monitoring of Certified phenotype opportunities. assays to gene via being an of function stages primarily and application upgrade our various ISO a we like situ quotient have will progression would program, and reading active base in that reagents. compliance. having as manufacturing that including on allow hybridization confidence and Farmingdale inflammation are believe with development. location molecular to and flow and build
be We Medicare levels. believed previously on commented to have what is PAMA impending Medical reimbursement
important. hold shortly year. adaptable which of the With affordable impacting of These into now services diagnostic I our Enzo of first the economic implementation call national that more to like and makes vision the laboratories, high the provider which of open wellbeing after nation's even will transforming timely the The a easily for questions. of and independent quality, expected products of is possibility further the first and
